more than ‘thinking
outside of the box’
Our General Manager Germany, Tobias Weizel, said he feels lucky to be a part of Novocure’s mission of bringing a profoundly different cancer treatment to patients worldwide.
Learn More
a decade of working
for Novocure
Sharyn Ruperti, Clinical Trial Manager, discusses her lengthy career at Novocure. Read about her views on the evolution of the company and what sets us apart.
Learn More
the science
of research
Our Director of Science, Ze’ev Bomzon, discusses his research on Tumor Treating Fields and the importance of effectively explaining the technology.
Learn More
2016 Novocure
annual report
View our 2016 Annual Report to learn where we've been and where we are headed in 2017 and beyond.
Learn Moretreating cancer with electric fields
treating cancer with electric fields
Surgery, chemotherapy and radiation are the best-known methods for treating cancer. At TEDMED in 2011, our Executive Chairman Bill Doyle presents our therapy, Tumor Treating Fields, as a potential fourth modality in cancer care.
the story
of Novocure
In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with more than 450 employees and operations in the U.S., Europe and Asia.
Learn More
Tumor Treating Fields, or TTFields, are low intensity, alternating electric fields.
TTFields disrupt cancer cell division through physical interactions with key molecules during mitosis. Our non-invasive treatment targets solid tumors.
OUR THERAPY
explore our clinical pipeline.
Our research shows that TTFields have an antimitotic effect in more than 15 solid tumor types in culture and in eight in vivo tumor models.
OUR PIPELINE
we are dedicated to improving the lives of cancer patients.
Patients remain at the heart of the work we do every day. Learn more about our patients, their families and the people working to deliver patient-forward therapies to treat cancer.
PATIENT-FORWARD